Drugs / MTR-601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06117020 | Sep 2023 → Oct 2024 | cerebral palsy, dystonic disorder, hereditary spastic paraplegia, multiple sclerosis +2 | Motric Bio | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06830642 | Feb 2025 → Jul 2026 | cervical dystonia | Motric Bio | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTR-601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06830642 ↗ |
| Action | Inhibit | “a highly selective fast twitch myosin 2 ATPase inhibitor” NCT06117020 ↗ |
| Route | Oral | “oral MTR-601” NCT06117020 ↗ |